Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal Cancer (COBEQOL)

Centre Hospitalier Universitaire de Besancon

Status: Unknown

Conditions: Quality of Life; Metastatic Colorectal Cancer

Treatments: Drug: Bevacizumab

Study type: Observational

Funder types: Other

Identifiers

NCT02842294

P/2012/151

Details and patient eligibility

About

The primary aim of this french multicenter national study is to assess and compare time to quality of life score deterioration (targeted dimensions : global health, fatigue and emotional functionning of EORTC QLQC30 according to the first line chemotherapy associated with bevacizumab in metastatic colorectal patients.

Enrollment: 320 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• age> 18years
• metastatic colorectal cancer (non resectable)
• 1st chemotherapy including bevacizuman

Exclusion criteria

• treatment contre-indication

Trial design

320 participants in 3 patient groups

irinotecan based chemotherapy

Description:

patients having a 1st line doublet chemotherapy including irinotecan

Treatment:

Drug: Bevacizumab

oxaliplatin based chemotherapy

Description:

patients having a 1st line doublet chemotherapy including oxaliplatin

Treatment:

Drug: Bevacizumab

triplet chemotherapy

Description:

patient having a 1st line triplet chemotherapy including oxaliplatin / irinotecan this cohort was added while primary objective was to compare doublet chemotherapy

Treatment:

Drug: Bevacizumab